Fc-FGF21 Variant Fusion for Extended Half-Life Metabolic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved FGF21 therapies with clinically acceptable dosing regimens for the treatment of metabolic disorders and reduction of cardiovascular risk in patients.
Innovation Solution
Development of genetically engineered FGF21 variants, such as V103, stabilized via a novel disulfide bond and fused to human IgG1 Fc, which significantly enhances half-life and potency, allowing for effective treatment and management of metabolic disorders and cardiovascular risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If wild-type FGF21 is used as therapy, then metabolic benefits are achieved, but half-life is too short requiring frequent dosing
Solution Approach 1:
The patent merges FGF21 with the Fc fragment of human IgG1 to create a fusion protein. This combination extends half-life by utilizing the Fc region's interaction with neonatal Fc receptors (FcRn) for recycling and protection from degradation, while maintaining the metabolic benefits of FGF21. The fusion protein achieves this through covalent linkage between the FGF21 molecule and Fc fragment.
Solution Approach 2:
The patent modifies the molecular structure of FGF21 by changing parameters such as adding an Fc fusion domain, which fundamentally alters the pharmacokinetic properties. This structural parameter change transforms the short half-life of wild-type FGF21 into an extended half-life formulation suitable for less frequent dosing.
2Duration of action of moving object
If FGF21 analogs are developed to extend half-life, then dosing frequency improves, but protein stability and folding may be compromised
Solution Approach 1:
The patent uses the Fc fragment as an intermediary structure that provides both structural stability and extended half-life. The Fc region acts as a stable scaffold that maintains proper folding while its unique properties (FcRn interaction) confer prolonged circulation time. This intermediary approach resolves the contradiction between stability and half-life extension.
3Reliability
If FGF21 is administered at higher doses to improve efficacy, then metabolic effects enhance, but safety and tolerability concerns increase
Solution Approach 1:
The patent changes the pharmacokinetic parameters of FGF21 through fusion with Fc, resulting in extended half-life and altered clearance characteristics. This parameter change allows for reduced dosing frequency and potentially lower total dose requirements, improving the efficacy-safety profile by reducing exposure to high doses while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FGF21 variant V103 demonstrates substantial reductions in body weight, glucose, insulin, serum TGs, liver TG content, hepatic lipid, fibrosis, and inflammation, providing clinical benefits in treating conditions like NAFLD/NASH and insulin resistance.
Implementation Method 1
Fibroblast growth factor 21 (FGF21) is thought to act on liver and adipose tissue to improve insulin sensitivity, lower triglycerides, and reduce adiposity
Implementation Method 2
stabilized via introduction of a novel disulfide bond
Data Source
AI summary
Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.